A Long-Term Follow-up Study of Subjects With Gaucher Disease Who Previously Received AVR-RD-02

Stopped early

Conditions studied: Type 1 Gaucher Disease

In brief

This is a multicenter, multinational long-term follow-up study to assess the long-term safety and durability of effect of AVR-RD-02 treatment in subjects who previously received AVR-RD-02 treatment (single dose administration).

Key facts

Study ID

NCT04836377

Run by

AVROBIO

People needed

4

Starts

2021-07-06

Expected to finish

2023-08-21

Last updated by the study team

2023-08-29

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject must have been enrolled and received AVR-RD-02 as single dose administration
• Subject must be willing and able to provide written informed consent for the AVRO-RD-02-LTF01 study in accordance with applicable regulations and guidelines and to comply with all study visits and procedures.

You may not qualify if…

• Subject is currently enrolled in an AVROBIO-sponsored AVR-RD-02 treatment study.

Where it is running

• University of Iowa — Iowa City, Iowa, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• M.A.G.I.C. Clinic Ltd — Calgary, Calgary Alberta, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.